HRS 5965
Alternative Names: HRS-5965Latest Information Update: 28 Nov 2025
At a glance
- Originator Chengdu Suncadia Medicine
- Class Anti-inflammatories; Urologics
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III IgA nephropathy; Paroxysmal nocturnal haemoglobinuria
- No development reported Glomerulonephritis
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for phase-I development in Glomerulonephritis(In volunteers) in China (PO, Tablet)
- 17 Aug 2025 Chengdu Suncadia Medicine completes a phase I trial drug-drug interaction trial (In volunteers) in China (PO, Capsule) (NCT07040787)
- 31 Jul 2025 Chengdu Suncadia Medicine completes a pase-III clinical trial in Paroxysmal nocturnal haemoglobinuria in China (PO) (NCT06593938)